Hong Kong Market Movers: Zai Lab Ltd (09688) Surges Over 13% on Q2 Product Revenue Growth and Promising Pipeline Catalysts

Stock News09:40

Zai Lab Ltd (09688) shares surged more than 13% on Friday, trading up 12.11% at HK$16.29 as of press time, with a trading volume of HK$69.7 million.

The rally follows the company's release of its second-quarter 2026 financial results and recent business highlights on the evening of August 6. The report showed total revenue of US$106.3 million for the second quarter of 2026, with net product revenue reaching US$105.8 million, a sequential increase of 11% from the previous quarter. This growth was driven by the steady performance of ZEJULA and the continued expansion of efgartigimod sales.

Notably, Zai Lab Ltd has advanced multiple global oncology and immunology pipeline programs toward key clinical and registration milestones. The company expects to announce several significant pipeline catalysts in the second half of 2026. Among these, phase 1 global data for zoci combined with a PD-L1 inhibitor as a first-line treatment for small cell lung cancer (SCLC) will be presented at the 2026 ESMO Congress. Additionally, a registration-enabling phase 3 study is planned to be initiated later this year. The global phase 1/1b study for ZL-1503 is progressing steadily, with initial first-in-human data anticipated in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133659634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133659634","market":"nz","top_or_hot":-1,"title":"Hong Kong Market Movers: Zai Lab Ltd (09688) Surges Over 13% on Q2 Product Revenue Growth and Promising Pipeline Catalysts","media":"Stock News","content":"<p><b>Zai Lab Ltd</b> (<b>09688</b>) shares surged more than 13% on Friday, trading up 12.11% at HK$16.29 as of press time, with a trading volume of HK$69.7 million.<br><br>The rally follows the company's release of its second-quarter 2026 financial results and recent business highlights on the evening of August 6. The report showed total revenue of US$106.3 million for the second quarter of 2026, with net product revenue reaching US$105.8 million, a sequential increase of 11% from the previous quarter. This growth was driven by the steady performance of ZEJULA and the continued expansion of efgartigimod sales.<br><br>Notably, <b>Zai Lab Ltd</b> has advanced multiple global oncology and immunology pipeline programs toward key clinical and registration milestones. The company expects to announce several significant pipeline catalysts in the second half of 2026. Among these, phase 1 global data for zoci combined with a PD-L1 inhibitor as a first-line treatment for small cell lung cancer (SCLC) will be presented at the 2026 ESMO Congress. Additionally, a registration-enabling phase 3 study is planned to be initiated later this year. The global phase 1/1b study for ZL-1503 is progressing steadily, with initial first-in-human data anticipated in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Market Movers: Zai Lab Ltd (09688) Surges Over 13% on Q2 Product Revenue Growth and Promising Pipeline Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Market Movers: Zai Lab Ltd (09688) Surges Over 13% on Q2 Product Revenue Growth and Promising Pipeline Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zai Lab Ltd</b> (<b>09688</b>) shares surged more than 13% on Friday, trading up 12.11% at HK$16.29 as of press time, with a trading volume of HK$69.7 million.<br><br>The rally follows the company's release of its second-quarter 2026 financial results and recent business highlights on the evening of August 6. The report showed total revenue of US$106.3 million for the second quarter of 2026, with net product revenue reaching US$105.8 million, a sequential increase of 11% from the previous quarter. This growth was driven by the steady performance of ZEJULA and the continued expansion of efgartigimod sales.<br><br>Notably, <b>Zai Lab Ltd</b> has advanced multiple global oncology and immunology pipeline programs toward key clinical and registration milestones. The company expects to announce several significant pipeline catalysts in the second half of 2026. Among these, phase 1 global data for zoci combined with a PD-L1 inhibitor as a first-line treatment for small cell lung cancer (SCLC) will be presented at the 2026 ESMO Congress. Additionally, a registration-enabling phase 3 study is planned to be initiated later this year. The global phase 1/1b study for ZL-1503 is progressing steadily, with initial first-in-human data anticipated in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1133659634","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133659634","pubTimestamp":1786066817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zai Lab Ltd (09688) shares surged more than 13% on Friday, trading up 12.11% at HK$16.29 as of press time, with a trading volume of HK$69.7 million.The rally follows the company's release of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","09688":"再鼎医药","KCAI":"KraneShares China Alpha Index ETF","ZLAB":"再鼎医药","BK4531":"中概回港概念","BK4139":"生物科技","VXUS":"国际股票ETF-Vanguard","BK4526":"热门中概股","BK4588":"碎股","BK1588":"回港中概股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4548":"巴美列捷福持仓","BK1574":"生物医药B类股","BK4585":"ETF&股票定投概念"},"translate_title":"香港市场推动者：再鼎医药有限公司 (09688) 因第二季度产品收入增长和有希望的管道催化剂飙升超过 13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1,"ZLAB":1,"KCAI":1,"VXUS":1},"content_text":"Zai Lab Ltd (09688) shares surged more than 13% on Friday, trading up 12.11% at HK$16.29 as of press time, with a trading volume of HK$69.7 million.The rally follows the company's release of its second-quarter 2026 financial results and recent business highlights on the evening of August 6. The report showed total revenue of US$106.3 million for the second quarter of 2026, with net product revenue reaching US$105.8 million, a sequential increase of 11% from the previous quarter. This growth was driven by the steady performance of ZEJULA and the continued expansion of efgartigimod sales.Notably, Zai Lab Ltd has advanced multiple global oncology and immunology pipeline programs toward key clinical and registration milestones. The company expects to announce several significant pipeline catalysts in the second half of 2026. Among these, phase 1 global data for zoci combined with a PD-L1 inhibitor as a first-line treatment for small cell lung cancer (SCLC) will be presented at the 2026 ESMO Congress. Additionally, a registration-enabling phase 3 study is planned to be initiated later this year. The global phase 1/1b study for ZL-1503 is progressing steadily, with initial first-in-human data anticipated in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133659634","isCrawlerRequest":true}